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Abstract
Objectives: The task of this working group was to update the knowledge about the 
use of drugs and biologicals affecting healing of soft tissue and bone during implant 
treatment or procedures associated with it. Moreover, the impact of titanium parti‐
cles and biocorrosion on complications and implant survival has been analysed.
Materials and Methods: The literature in the areas of interest (platelet concentrates, 
antiresorptive drugs as well as implant–host interaction) was screened using systematic 
reviews for the former two areas, whereas a narrative critical review was performed for 
the latter topic. Two manuscripts on platelet concentrates, one manuscript on antire‐
sorptive drugs and one manuscript on the effects of biocorrosion, were presented for 
group analysis with subsequent discussion in the plenum and final consensus approval.
Results: Results and conclusions of the individual reviews of the three topics are 
presented in the respective papers. Conclusions of the group on strengths and 
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1  | THE USE OF PL ATELET PREPAR ATIONS 
TO ENHANCE THE OUTCOMES OF 
IMPL ANT‐REL ATED THER APIES:  A 
SYSTEMATIC RE VIE W
Platelet concentrates (PCs) are blood extracts, obtained after pro‐
cessing a whole blood sample through centrifugation. Different 
techniques leading to a variety of preparations have been developed. 
For the preparation of platelet‐rich plasma (PRP) and plasma rich in 
growth factors (PRGF), citrated blood is used during the centrifu‐
gation process to avoid coagulation. This results in liquid PRP and 
PRGF. For the use in gel form, thrombin and/or calcium chloride is 
added to induce fibrin polymerization creating a weak fibrin network. 
For the preparation of platelet‐rich fibrin (PRF), no anticoagulant and 
no thrombin/calcium chloride is used and only one step of centrifu‐
gation is employed during which coagulation occurs.
1.1 | Focus question
Is there any additional benefit from the use of PCs over traditional 
approaches in terms of clinical and radiographic outcomes in implant 
therapy including implant placement as well as associated proce‐
dures such as ridge preservation, ridge augmentation, sinus floor 
augmentation and treatment of peri‐implantitis?
1.2 | Summary
1.2.1 | Dental implant placement
Coating of implants with PRP during implant insertion has shown no 
benefits (1 Randomized Clinical Trial ‐RCT‐ & 1 Controlled Clinical trial 
–CCT‐, 40 patients, High Risk of Bias ‐HRB). The coating of implants 
with PRF before or during implant insertion has shown a significant 
increase in Implant Stability Quotient ISQ values. (2‐12 ISQ units, 
6 weeks)(2 RCTs, 40 patients, 104 implants, Unclear or Low Risk of Bias 
URB‐LRB). The use of PRF membranes in conjunction with implant 
placement to cover the bone before tissue closure have shown less 
bone loss during the first three months (0.35 mm) (1 RCT, 20 patients., 
URB).
1.2.2 | Ridge preservation
This question was answered separately for the use of PCs alone 
compared to no treatment and the use of grafting materials with/
without PCs.
Use of PCs alone
For the use of PRP, no data have been reported in the reviewed 
paper on the reduction in bone resorption but improved soft tis‐
sue healing was observed compared to no treatment (1 RCT, 23 
patients, LRB). When PRGF was used for alveolar preservation, no 
benefits have been shown (1 CCT, 28 patients, HRB). The use of 
PRF after dental extraction with a flapless approach has shown 
to provide less alveolar resorption and an increased bone fill at 
three months (2.1 mm ‐29%‐ less horizontal ridge resorption, 30% 
more socket filling) (1 RCT, 22 patients, LRB) and is associated with 
improved soft tissue healing at one week (1 RCT, 26 p., URB) com‐
pared to no treatment.
Use of PCs in combination with grafting materials:
No benefits have been reported when PRP was used in combina‐
tion with decalcified freeze‐dried bone allograft (DFDBA) as alveolar 
weaknesses of available evidence as well as consensus statements and directions for 
further research are provided in this study.
The following papers were subject to group discussions and formed the basis for the 
consensus statements:
Stähli A, Strauss FJ, Gruber R. (2018) The use of platelet‐rich‐plasma to enhance the 
outcomes of implant‐related therapies: a systematic review
Strauss FJ, Stähli A, Gruber R. (2018) The use of platelet‐rich‐fibrin to enhance the 
outcomes of implant‐related therapies: a systematic review
Mombelli A, Hashim D, Cionca N. (2018) What is the impact of titanium particles and 
bio‐corrosion on implant survival and complications? A critical review
Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Morten Schiødt, Klinge B. (2018) 
The effect of antiresorptive drugs on implant therapy: a systematic review.
K E Y W O R D S
alveolar ridge preservation, antiresorptive drugs, bisphosphonates, corrosion, dental implants, 
guided bone regeneration sinus floor elevation, hormone replacement therapy, implant 
therapy, medication‐related osteonecrosis of the jaws, peri‐implantitis, platelet‐rich fibrin, 
platelet‐rich plasma, systematic review, titanium
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filling material (1 RCT, 53 patients, URB). PRF used in combination 
with DFDBA and a collagen membrane improved horizontal ridge 
preservation (0.61 mm) (1 RCT, 36 patients, URB). PRF used in combi‐
nation with autogenous bone has shown no significant clinical ben‐
efits (1 RCT, 12 patients, URB).
1.2.3 | Ridge augmentation
The use of PRP during ridge augmentation procedures has shown 
benefits with respect to crest width (0.3‐0.4 mm) and height 
(0.4 mm) (2 RCTs, 62 patients, LRB) and higher soft tissue stability 
showing significantly less graft exposures (28%). The addition of 
PRF to a synthetic graft material in ridge augmentation has shown 
no benefits (1 RCT, 82 patients, URB).
1.2.4 | Sinus floor augmentation
No RCTs or CCTs evaluating the sinus floor augmentation with PRF, 
PRP or PRGF alone have been identified.
The addition of PRP to autologous bone has shown no benefits 
in terms of implant survival rate, implant stability, augmentation 
height, marginal bone level changes, bone density, volume of lamel‐
lar and woven bone, volume of new bone, bone graft resorption, 
angiogenesis and soft tissue healing (5 RCT, 2 CCT, 167 patients, LRB‐ 
HRB). Some papers reported short‐term improvement on outcome 
measures related to bone formation and densitometric values (2 
RCTs and 1 CCT, 81 patient, URB). The clinical relevance of these pa‐
rameters is unclear. The use PRP in combination with β‐TCP (1 RCT, 
35 p., URB) or xenografts (2 RCTs, 1 CCT, 127 patients, URB‐LRB) has 
shown no clinical benefits.
The use of PRF in combination with deproteinized bovine bone 
mineral (DBBM) has shown no additional benefits (2 RCTs, 73 pa‐
tients, LRB).
1.2.5 | Surgical treatment of peri‐implantitis
No RCTs/CCTs on the use of PRP / PRGF in treatment of peri‐im‐
plantitis were found. The use of PRF in open flap debridement has 
shown improvement on soft tissue‐related parameters such as prob‐
ing depth reduction (0.5 mm), clinical attachment gain (1.4 mm) and 
reduction in peri‐implant soft tissue recession (0.9 mm) (1 RCT, 19 
patients, URB).
1.3 | Consensus statements
The RCTs and CCTs included in this review were short‐term 
(mainly between 3 weeks and 6 months) and the great majority 
of them had small sample sizes with no sample size calculation 
described. Conclusion on individual procedures analysed is based 
mostly on one or two RCTs. Given the limitation with the large 
majority of included studies being underpowered, the result‐
ing evidence hence is still weak and has to be considered with 
caution.
The use of PRP has been reported to be beneficial: 
• during alveolar ridge augmentation procedures by increasing 
ridge width and height as well as reducing the rate of graft expo‐
sure (2 RCTs).
The use of PRP has shown no benefits: 
• as sole material or in combination with DFDBA in alveolar ridge 
preservation (2 RCTs),
• during implant placement with respect to implant stability and 
marginal bone loss (1 RCT, 1 CCT).
• in sinus lift techniques when used in combination with bone or 
bone substitutes (10 RCTs, 4 CCTs)
The use of PRGF has not shown benefits for ridge preservation and has 
not been evaluated in other indications.
The use of PRF has been reported to be beneficial: 
• as sole material or in combination with non‐autogenous grafting 
material in limiting post‐extraction alveolar ridge resorption (3 
RCTs). The beneficial effect of PRF in combination with grafting 
material vs. graft material alone is substantially smaller than the 
use of PRF alone vs. no treatment.
• during implant placement by improving early implant ISQ values 
(2 RCTs) and reducing early marginal bone loss (1 RCT).
• in open flap debridement in peri‐implantitis treatment by improv‐
ing clinical attachment levels, and reducing marginal tissue reces‐
sion and probing pocket depth (1 RCT).
The use of PRF has shown no benefits: 
• in sinus lift techniques when used in combination with autoge‐
nous bone or bone substitutes (2 RCTs)
1.4 | Clinical recommendations
For all PCs used, no negative side effects have been reported. 
Recommendations are made based on the evidence for clinical benefits 
taking into consideration the small number of underpowered studies 
that could be included for individual indications. Hence, the resulting ev‐
idence is still weak and the strength of clinical recommendations is low.
In ridge preservation procedures, PRF can be used as sole ma‐
terial or in combination with non‐autogenous graft material to limit 
alveolar ridge resorption after dental extraction. The use of PRP or 
PRGF in these indications does not appear to be recommendable 
alone or in combination with graft materials for this indication due 
to a lack of effect.
The use of PRF during implant placement cannot yet be recom‐
mended due to limited and premature clinical evidence.
The use of PRF and PRP in sinus augmentations in combination 
with grafting materials appears not to be recommendable due to a 
lack of effect.
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The use of PRF as an adjunct to open flap debridement in the 
treatment of peri‐implantitis cannot yet be recommended due to 
limited / premature data.
The use of PRP in lateral augmentation procedures may be rec‐
ommendable but the evidence is low.
1.5 | Recommendations for future research
Future RCTs should: 
• be adequately powered with appropriate sample size calculation.
• address implant‐related surgical procedures (ridge preservation, 
implant placement, sinus augmentation techniques, peri‐implanti‐
tis treatment) to enhance the existing evidence.
• assess potential benefits in locally compromised areas and sys‐
temically compromised patients.
• address patient‐reported outcome measures (PROMs) (reduction 
in pain/swelling/oedema).
• include elements of relevant health economics / cost aspects.
2  | WHAT IS THE IMPAC T OF TITANIUM 
PARTICLES AND BIOCORROSION ON 
IMPL ANT SURVIVAL AND COMPLIC ATIONS? 
A CRITIC AL RE VIE W
Titanium is an abundant element in the earth crust, and its salts are 
widely used in all kinds of products of modern life Thus, every in‐
dividual living in a developed country is invariably and continually 
exposed to TiO2. It is used as micro‐ or nanoparticles in foods, tooth‐
pastes, cosmetics, sunscreens and medicine pills. Nevertheless, con‐
cerns have been raised regarding the potential of titanium particles 
located in peri‐implant tissues to induce host reactions that may con‐
tribute to complications in dental implant therapy. Micro‐particles 
and nanoparticles differ in their action on the cells. Nanoparticles 
were described as more biologically reactive and thus potentially 
more harmful than micro‐particles. The purpose of this review was 
to analyse the current evidence regarding the association between 
the release of titanium particles and the biological complications 
of dental implants. In pursuit of this, the following questions were 
elaborated:
2.1 | What are the potential origins of titanium 
particles found in peri‐implant tissues?
The following mechanisms have been suggested to be involved in 
the release of titanium particles from surfaces of dental implants: 
mechanical wear, contact with chemical agents, effects of biofilm 
adhesion and inflammatory cells.
In vitro and in vivo experiments show that particles can be re‐
leased from surfaces of dental implants in a process called “tribo‐
corrosion.” It involves mechanical wear and environmental factors. 
Mechanical wear occurs during placement of the implants, as a result 
of micro‐motion between implant parts and suprastructures and in 
the context of mechanical prophylaxis and therapy of mucositis and 
peri‐implantitis.
In vitro studies demonstrate that acidic environments induced by 
bacterial biofilms and/or inflammatory processes trigger the release 
of titanium particles, a process referred to as “biocorrosion.”
Animal experiments have also shown that particles originating 
from external sources can accumulate in the gingival tissues irre‐
spective of existing implants.
2.2 | What is the evidence that titanium particles 
have cytotoxic and/or pro‐inflammatory effects?
In vitro experiments assessed effects of titanium ions or particles 
on bone and soft tissue. Titanium debris can disturb the balance be‐
tween bone formation and bone resorption in two ways: directly, 
by differentially activating osteoclasts and osteoblasts, or indirectly, 
by stimulating the secretion of inflammatory cytokines produced by 
macrophages and lymphocytes. Epithelial cells and fibroblasts have 
shown reactivity to titanium particles. Research has also identified 
factors modulating such effects, notably particle size and associa‐
tion with molecules like LPS.
2.3 | What is the biological plausibility for a link 
between titanium particles and corrosion in peri‐
implant tissues and biological complications?
Titanium particles are commonly detected in healthy and diseased peri‐
implant mucosa alike, and even in gingiva of individuals without titanium 
implants. Thus, there is poor specificity for the association between the 
presence of particles and pathology. 15 available studies reporting data 
on titanium particles in tissues adjacent to dental implants (mucosa over‐
lying titanium cover screws during submerged healing of two‐piece im‐
plants, mucosa from peri‐implantitis lesions, mucosa with marked clinical 
signs of inflammation, mucosa from implants without clinical signs of pa‐
thology, gingiva from healthy teeth) indicate there is a tendency to find 
more titanium in close proximity of the implant surface and in specimens 
from diseased sites. However, evidence for a simple cause and effect 
relationship between titanium particles and biological implant compli‐
cations does not exist. In vitro experiments demonstrate that titanium 
particles can interfere with cell function, possibly promoting inflamma‐
tion under some circumstances. Moreover, release of titanium particles 
in acidic environments induced by bacterial biofilms and/or inflammatory 
processes have been shown in vitro. The true impact of these findings on 
patients with titanium implants, however, is not determined.
2.4 | What is the evidence for hypersensitivity to 
titanium?
The evidence for existence of hypersensitivity against titanium is 
weak. It consists essentially in a limited number of cases where a 
temporal association between exposure to titanium and occur‐
rence of tissue reactions could be demonstrated, and in finding such 
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reactions in tissues in proximity to implanted titanium. There is no 
consistency in findings observed by different persons in different 
places with different samples. Also, there is poor specificity as the 
observed reactions could be caused by other factors associated with 
the placement of implants. Coherence between epidemiological and 
laboratory findings consists in two studies presenting results from 
selected populations.
2.5 | What is the evidence for advocating the use of 
hypersensitivity testing in the context of treatment 
planning?
The validity of patch testing is questionable because it evaluates 
reactions to epidermal rather than oral mucosal contact. Oral mu‐
cosa and skin have different permeability and immunological prop‐
erties, as reflected in the number of antigen‐presenting cells. There 
is controversy about the validity of lymphocyte immuno‐stimulation 
assays, especially with regards to the unclear rate of false‐positive 
results.
Studies showing clinical utility are missing. Test positive and neg‐
ative patients treated with titanium or non‐titanium implants should 
be monitored prospectively to assess the differential incidence of 
biological complications.
2.6 | What is the evidence that the presence of 
titanium particles has an impact on implant survival/
success and biological complications?
In terms of multiple and/or recurrent non‐integration, or spontane‐
ous loss of osseointegration, there is no direct evidence that tita‐
nium particles have an impact on implant survival/success. Aseptic 
loosening has not been limited to titanium implants but has been 
reported for zirconia implants alike.
For peri‐implantitis, it has been suggested that the incidence 
is lower for zirconia than titanium implants. However, robust 
data from prospective studies to confirm this are currently 
unavailable.
Although all currently available protocols for therapy of mucosi‐
tis and peri‐implantitis further contaminate the peri‐implant tissues 
with titanium particles, they have a certain degree of success. Some 
protocols even include the placement of titanium granules for the 
treatment of peri‐implantitis lesions.
Hence, based on the current level of evidence, and the small 
number of reported cases, it is unlikely that adverse biological reac‐
tions elicited by titanium play a major role in the aetiology of peri‐
implant diseases.
2.7 | Clinical recommendations
Current evidence does not suggest that there is an increased risk of 
an adverse effect of titanium particles that would reason considera‐
tions for implant material selection other than titanium.
There is insufficient evidence to recommend immunological 
testing related to implant material for planning and monitoring of 
implant therapy.
2.8 | Recommendations for research
Future research should: 
• develop appropriate animal models to explore the effects of arti‐
ficial contamination of peri‐implant tissues with titanium particles 
for in vivo research.
• assess immunological and tissue reactions to placement of tita‐
nium and non‐titanium implants and prospective monitoring of 
peri‐implant tissue conditions.
• perform prospective monitoring of immunological and tissue reac‐
tions to implant placement in relation to immunological risk factors
3  | THE EFFEC T OF ANTIRESORPTIVE 
DRUGS ON IMPL ANT THER APY: A 
SYSTEMATIC RE VIE W
Antiresorptive drugs (ARDs) are used predominantly for the treat‐
ment of osteoporosis and management of skeletal metastases of 
malignancies, to prevent events like fractures, and limit pain and 
metastatic spread. Use of ARDs has traditionally been divided ac‐
cording to the route of administration (i.e. oral, subcutaneous, in‐
travenous). Current understanding, however, is that dose rather 
than route of administration is important. Thus, low‐ and high‐dose 
ARDs can be today administered through all three routes. Primarily, 
low‐dose is used for osteoporosis treatment, whereas high‐dose 
is used in cancer patients with bone metastases. Patients on ARD 
have a risk of developing medication‐related osteonecrosis of the 
jaw (MRONJ), a specific complication directly related to this type 
of drugs that can have devastating consequences for the individual 
patient.
Herein,	24	studies	including	≥	10	patients	with	bisphosphonate	
(BP) intake (mainly low‐dose for osteoporosis treatment) and con‐
trol patients not taking BP were identified. Collectively, some type 
of information was provided regarding: implant success, failure, or 
loss, in 23 studies; bone grafting procedures in 11 studies; MRONJ 
in 17 studies; peri‐implantitis in 9 studies. Precise figures were 
reported regarding: a) implant loss in 12 studies on patient level 
(1218 BP patients; 1144 controls) and in 15 studies on the implant 
level (2849 implants in BP patients; 3946 implants in controls); b) 
grafting procedures in 6 studies on implant/site level (336 BP pa‐
tients); c) MRONJ associated with implants in 16 studies on patient 
level (1390 BP patients). In addition, 7 case series on implant‐as‐
sociated MRONJ including 11 to 27 patients were identified (116 
in total).
The major bulk of evidence on ARD intake in implant therapy de‐
rives from studies reporting on low‐dose oral BPs. There are limited 
data on possible detrimental effects of high‐dose BPs and newer type 
98  |     SCHLIEPHAKE Et AL.
ARDs (e.g. denosumab) in conjunction with implant therapy. It is im‐
portant to note that the evidence of this report is limited due to the 
fact that it derives from studies with low quality in terms of design, 
quality of reporting and number of included cases and/or controls.
To address the large number of possible combinations of dif‐
ferent ARDs and ARD dosages, routes of administration as well as 
timing of implant placement / start of ARD therapy, the following 
questions were handled separately:
3.1 | Are implant placement and/or bone 
augmentation procedures associated with 
increased risk of implant loss or other 
complications in osteoporosis patients on low‐dose 
ARD intake?
The currently available evidence indicates that patients on low‐dose 
oral BP do not lose more implants nor get more implant‐related compli‐
cations (i.e. peri‐implant marginal bone loss, peri‐implantitis) compared 
to implant patients without BP intake. Implant loss in patients on low‐
dose BP has been reported in few studies, and these were predomi‐
nantly early losses (i.e. within short time post‐installation/post‐loading). 
The available knowledge regarding success or safety of bone grafting 
procedures in conjunction with implant installation is too limited to 
draw conclusions.
It has to be kept in mind that all patients on low‐dose ARD (BP 
and denosumab) intake, including implant patients, do have a risk 
of MRONJ. MRONJ in association with implant therapy has been 
reported to occur within a short timeframe of weeks (i.e. implant 
surgery was assumed as the trigger) to several years after implant 
installation, even in the case of low‐dose oral BP intake. The inci‐
dence of MRONJ in implant patients on low‐dose oral BP is currently 
unknown, albeit it appears to be low.
3.2 | Does low‐dose oral BP intake in osteoporosis 
patients compromise the longevity of existing 
implants?
There is no evidence that low‐dose oral BP intake compromises 
the longevity of existing implants. However, based on case se‐
ries, there is evidence that MRONJ may appear associated with 
implants in patients with low‐dose oral BP intake, resulting in im‐
plant loss. The incidence of implant‐associated MRONJ in these 
patients is currently unknown, albeit it appears to be low.
3.3 | Does low‐dose subcutaneous or intravenous 
ARD administration in osteoporosis patients have an 
impact on the outcome of implant therapy in terms of 
implant losses and/or complications?
There is insufficient data to draw conclusions on the possible effect of 
low‐dose subcutaneous and intravenous ARD administration on the 
outcome of implant placement or pre‐existing implants in osteoporo‐
sis patients.
3.4 | Does duration of low‐dose ARD intake 
in osteoporosis patients have an impact on the 
outcome of implant therapy in terms of implant 
losses and/or complications?
The risk of MRONJ in all patients on low‐dose ARD (BP and deno‐
sumab) intake increases with increased duration of intake. Based 
on currently available data, the effect of the duration of low‐dose 
ARD intake in implant patients on the risk of implant loss or the de‐
velopment of implant‐associated MRONJ is unclear. Six studies on 
single‐patient data reported that MRONJ associated with implants 
in patients on BP for osteoporosis appeared mainly >36 months 
after start of drug intake (in 29 out of 41 patients; 71%).
3.5 | Does ARD dose (low vs. high) have an impact 
on the outcome of implant therapy in terms of implant 
losses and/or complications?
Based on currently available data, the effect of dose on the survival 
of implants placed in patients with ARD intake is unclear. In general, 
the risk of MRONJ is higher in cancer patients on high‐dose ARD 
than in osteoporosis patients on low‐dose ARD (BP and denosumab). 
Data from 6 studies on single‐patient data show MRONJ appearing 
in	cancer	patients	MRONJ	mainly	≤	36	months	of	BP	intake	(20	out	
of 32 patients; 64%), whereas it occurred in patients on BP for mainly 
>36 months after start of drug intake (in 29 out of 41 patients; 71%).
3.6 | Does the interruption of ARD intake 
(“drug holiday”) have an impact on the outcome of 
implant therapy in terms of implant losses and/or 
complications?
A “drug holiday” has been recommended in some published clinical 
guidelines. However, due to the lack of evidence, the benefits of this 
concept in implant therapy remain unclear.
3.7 | Consensus statements
• Implant therapy in patients receiving low‐dose oral BP for osteo‐
porosis treatment is not associated with an increased risk of im‐
plant loss or other complications compared to patients without 
BP intake.
• Current knowledge on the effect of low‐dose subcutaneous and 
intravenous ARD administration on implant therapy is insufficient 
to draw conclusions.
• Patients on low‐ and high‐dose ARD are at risk of developing 
MRONJ irrespective of implant therapy. The risk of MRONJ in‐
creases with dose and duration of ARD intake. The incidence of 
implant‐associated MRONJ in patients on low‐dose ARD (BP and 
denosumab) is currently unknown, albeit it appears to be low.
• The benefits of the “drug holiday” concept in implant therapy are 
unclear.
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3.8 | Clinical recommendations
• Low‐dose oral BP intake for osteoporosis treatment per se is not a 
contraindication for implant installation. There are no data on low‐
dose subcutaneous and intravenous ARD intake in conjunction with 
implant therapy to draw conclusions. However, based on epidemio‐
logical data, there is no reason to assume a higher risk of complica‐
tions in these groups of ARD compared to low‐dose oral BP intake.
• Currently, no recommendations can be given on bone grafting 
procedures in conjunction with implant therapy in patients on 
low‐dose ARDs. Individual patient assessment with a focus on 
known risk factors is mandatory, for example local factors, smok‐
ing, systemic diseases, comedications and duration of ARD intake.
• Based on information from tooth extraction studies on patients 
with high‐dose ARD intake, measures for primary intention 
healing (e.g. submerged implants), including prophylactic use of 
antibiotics and postoperative antiseptics (e.g. chlorhexidine), is 
recommended when implant therapy and/or bone grafting proce‐
dures are performed in patients with low‐dose ARD intake.
• A drug holiday should be only considered after consultation with 
the treating physician.
• Implant therapy and/or bone grafting procedures are currently 
not recommended in patients on high‐dose ARD intake.
3.9 | Future research
Future research should: 
• evaluate the potential benefits of prophylactic use of antibiotics 
in association with implant installation and/or bone augmentation 
procedures in patients with low‐dose ARD intake.
• evaluate the potential benefits of a drug holiday in association 
with implant installation and/or bone augmentation procedures in 
patients with low‐dose ARD intake.
• explore the potential for implant therapy in patients on high‐dose 
ARD in particular in comparison with alternative modes of treat‐
ment (removable prostheses) that can give rise to the occurrence 
of MRONJ themselves.
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